Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipoprotein(a) [Lp(a)] mRNA is the messenger RNA transcribed from the *LPA* gene, encoding apolipoprotein(a) [apo(a)]. The *LPA* gene contains a variable number of kringle IV type 2 (KIV-2) repeats, leading to significant size polymorphism. Lp(a) mRNA is primarily synthesized in the liver. Therapies targeting Lp(a) mRNA, such as antisense oligonucleotides (ASOs) and siRNAs, aim to reduce hepatic production of apo(a), thereby lowering circulating Lp(a) concentrations, an independent risk factor for cardiovascular disease.
Antisense oligonucleotide (ASO) mediated degradation or translational inhibition; siRNA mediated cleavage
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipoprotein A mRNA (Lp(a) mRNA).